ATNM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATNM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Actinium Pharmaceuticals's Enterprise Value is $155.00 Mil. Actinium Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-49.93 Mil. Therefore, Actinium Pharmaceuticals's EV-to-EBIT ratio for today is -3.10.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Actinium Pharmaceuticals's Enterprise Value is $155.00 Mil. Actinium Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-49.11 Mil. Therefore, Actinium Pharmaceuticals's EV-to-EBITDA ratio for today is -3.16.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Actinium Pharmaceuticals's Enterprise Value is $155.00 Mil. Actinium Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.08 Mil. Therefore, Actinium Pharmaceuticals's EV-to-Revenue ratio for today is 1,913.59.
The historical data trend for Actinium Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actinium Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 28.02 | 73.93 | 55.57 | 167.11 | 65.82 |
Actinium Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Enterprise Value | Get a 7-Day Free Trial | 151.08 | 111.29 | 81.52 | 65.82 | 148.10 |
For the Biotechnology subindustry, Actinium Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Actinium Pharmaceuticals's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Actinium Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 140.381736 | + | 0 | + | 1.572 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.541 | + | 0 | - | 76.677 |
= | 65.82 |
Actinium Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as
Enterprise Value (Q: Mar. 2024 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 230.173812 | + | 0 | + | 1.431 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.551 | + | 0 | - | 84.057 |
= | 148.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actinium Pharmaceuticals (AMEX:ATNM) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Actinium Pharmaceuticals's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 155.001 | / | -49.933 | |
= | -3.10 |
Actinium Pharmaceuticals's current Enterprise Value is $155.00 Mil.
Actinium Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.93 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Actinium Pharmaceuticals's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 155.001 | / | -49.109 | |
= | -3.16 |
Actinium Pharmaceuticals's current Enterprise Value is $155.00 Mil.
Actinium Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.11 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Actinium Pharmaceuticals's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 155.001 | / | 0.081 | |
= | 1,913.59 |
Actinium Pharmaceuticals's current Enterprise Value is $155.00 Mil.
Actinium Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Sandesh Seth | director | 300 E 93RD STREET, #20-B, NEW YORK NY 10128 |
Steve O'loughlin | officer: VP, Finance and Corporate Dev. | 955 HARTMAN RUN ROAD, MORGANTOWN WV 26507 |
Dale L. Ludwig | officer: Chief Scientific Officer | 21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028 |
Jeffrey W. Chell | director | 521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767 |
Ajit Shetty | director | 643 ZEEDIJK, KNOKKE C9 8300 |
Anil Kapur | officer: Chief Commercial Officer | 275 MADISON AVE, SUITE 702, NEW YORK NY 10016 |
Nitya G. Ray | officer: Executive Vice President | 14 BAYBURY COURT, EAST HANOVER NJ 07936 |
Mark Stanley Berger | officer: Chief Medical Officer | 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024 |
Memorial Sloan-kettering Cancer Center | 10 percent owner | 1275 YORK AVE., NEW YORK NY 10065 |
Sergio Traversa | director | 138 CANTERBURY LN, BLUE BELL PA 19422 |
C. David Nicholson, | director | 103 CHILDS ROAD, BASKIN RIDGE NJ 07092 |
Kaushik J Dave | director, officer: President and CEO | 4 WATER STREET, EDISON NJ 08820 |
Richard I Steinhart | director | 125 ELM STREET, NEW CANAAN CT 06840 |
Ahlb Holdings, Llc | 10 percent owner | C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065 |
Actinium Holdings, Ltd. | 10 percent owner | C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000 |
From GuruFocus
By PRNewswire PRNewswire • 05-11-2023
By PRNewswire • 08-21-2023
By PRNewswire PRNewswire • 04-19-2023
By PRNewswire PRNewswire • 04-19-2023
By PRNewswire PRNewswire • 04-28-2023
By PRNewswire • 12-11-2023
By PRNewswire • 11-14-2023
By PRNewswire • 06-23-2023
By PRNewswire • 06-26-2023
By PRNewswire • 08-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.